Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지
DOI QR코드

DOI QR Code

Survival Effect of Complete Multimodal Therapy in Malignant Pleural Mesothelioma

  • Received : 2022.05.18
  • Accepted : 2022.07.28
  • Published : 2022.10.05
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Malignant pleural mesothelioma (MPM) is an aggressive pleural malignancy, and despite all multimodal treatment modalities, the 5-year overall survival rate of patients with MPM is less than 20%. In the present study, we aimed to analyze the surgical and prognostic outcomes of patients with MPM who received multimodal treatment. Methods: In this retrospective, single-center study, the records of patients who underwent surgery for MPM between January 2010 and December 2020 at our department were reviewed retrospectively. Results: Sixty-four patients were included in the study, of whom 23 (35.9%) were women and 41 (64.1%) were men. Extrapleural pneumonectomy, pleurectomy/decortication, and extended pleurectomy/decortication procedures were performed in 34.4%, 45.3%, and 20.3% of patients, respectively. The median survival of patients was 21 months, and the 5-year survival rate was 20.2%. Advanced tumor stage (hazard ratio [HR], 1.8; p=0.04), right-sided extrapleural pneumonectomy (HR, 3.1; p=0.02), lymph node metastasis (HR, 1.8; p=0.04), and incomplete multimodal therapy (HR, 1.9; p=0.03) were poor prognostic factors. There was no significant survival difference according to surgical type or histopathological subtype. Conclusion: Multimodal therapy can offer an acceptable survival rate in patients with MPM. Despite its poor reputation in the literature, the survival rate after extrapleural pneumonectomy, especially left-sided, was not as poor as might be expected.

Keywords

References

  1. Popat S, Baas P, Faivre-Finn C, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2022;33:129-42. https://doi.org/10.1016/j.annonc.2021.11.005
  2. Opitz I, Furrer K. Preoperative identification of benefit from surgery for malignant pleural mesothelioma. Thorac Surg Clin 2020;30:435-49. https://doi.org/10.1016/j.thorsurg.2020.08.003
  3. Selcuk ZT, Coplu L, Emri S, Kalyoncu AF, Sahin AA, Baris YI. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey: analysis of 135 cases. Chest 1992;102:790-6. https://doi.org/10.1378/chest.102.3.790
  4. Beaucham C, King B, Feldmann K, Harper M, Dozier A. Assessing occupational erionite and respirable crystalline silica exposure among outdoor workers in Wyoming, South Dakota, and Montana. J Occup Environ Hyg 2018;15:455-65. https://doi.org/10.1080/15459624.2018.1447116
  5. Bertoglio P, Garelli E, Brandolini J, et al. Surgical management and reconstruction of diaphragm, pericardium and chest wall in mesothelioma surgery: a review. J Clin Med 2021;10:2330. https://doi.org/10.3390/jcm10112330
  6. Bueno R, Opitz I; IASLC Mesothelioma Taskforce. Surgery in malignant pleural mesothelioma. J Thorac Oncol 2018;13:1638-54. https://doi.org/10.1016/j.jtho.2018.08.001
  7. Berzenji L, Van Schil PE, Carp L. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res 2018;7:543-9. https://doi.org/10.21037/tlcr.2018.07.05
  8. Opitz I, Weder W. A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma. Ann Transl Med 2017;5:237. https://doi.org/10.21037/atm.2017.03.88
  9. Zhou N, Rice DC, Tsao AS, et al. Extrapleural pneumonectomy versus pleurectomy/decortication for malignant pleural mesothelioma. Ann Thorac Surg 2022;113:200-8. https://doi.org/10.1016/j.athoracsur.2021.04.078
  10. Kang SR, Bok JS, Lee GD, et al. Surgical options for malignant mesothelioma: a single-center experience. Korean J Thorac Cardiovasc Surg 2018;51:195-201. https://doi.org/10.5090/kjtcs.2018.51.3.195
  11. Klotz LV, Gruenewald C, Bulut EL, et al. Cytoreductive thoracic surgery combined with hyperthermic chemoperfusion for pleural malignancies: a single-center experience. Respiration 2021;100:1165-73. https://doi.org/10.1159/000517334
  12. Baas P, Daumont MJ, Lacoin L, et al. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: a nationwide CAS registry analysis from the I-O Optimise initiative. Lung Cancer 2021;162:185-93. https://doi.org/10.1016/j.lungcan.2021.11.001
  13. Bovolato P, Casadio C, Bille A, et al. Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol 2014;9:390-6. https://doi.org/10.1097/jto.0000000000000064
  14. Abdel-Rahman O, Elsayed Z, Mohamed H, Eltobgy M. Radical multimodality therapy for malignant pleural mesothelioma. Cochrane Database Syst Rev 2018;1:CD012605.
  15. Lang-Lazdunski L, Bille A, Lal R, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol 2012;7:737-43. https://doi.org/10.1097/jto.0b013e31824ab6c5
  16. Mangiameli G, Bottoni E, Cariboni U, et al. Single-center 20-year experience in surgical treatment of malignant pleural mesothelioma. J Clin Med 2022;11:4537. https://doi.org/10.3390/jcm11154537
  17. Lewis GD, Dalwadi SM, Farach A, Brian Butler E, Teh BS. The role of adjuvant radiotherapy in the treatment of pleural mesothelioma. Ann Surg Oncol 2019;26:1879-85. https://doi.org/10.1245/s10434-019-07235-9
  18. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763-72. https://doi.org/10.1016/S1470-2045(11)70149-8
  19. Ichiki Y, Goto H, Fukuyama T, Nakanishi K. Should lung-sparing surgery be the standard procedure for malignant pleural mesothelioma? J Clin Med 2020;9:2153. https://doi.org/10.3390/jcm9072153
  20. Sugarbaker DJ, Richards WG, Bueno R. Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann Surg 2014;260:577-82. https://doi.org/10.1097/SLA.0000000000000903
  21. Cao C, Yan TD, Bannon PG, McCaughan BC. Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Surg Oncol 2011;18:2973-9. https://doi.org/10.1245/s10434-011-1728-x
  22. Bedirhan MA, Cansever L, Demir A, et al. Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy? J Thorac Dis 2013;5:446-54. https://doi.org/10.3978/j.issn.2072-1439.2013.07.40
  23. Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36:1343-73. https://doi.org/10.1200/JCO.2017.76.6394